Abbott Laboratories
ABT NYSE· Health Care Equipment
Last close · Oct 26, 2026
$104.88
KIRA · Stoqly’s AI analyst, in plain words
- Abbott Laboratories had $44.3B of revenue in fiscal 2025, up 5.7% on the year before. Over five years, revenue changed +5.1% a year on average.
- Its operating margin was 18.2%, up 1.9 pts: of every 100 in sales, about 18 is left after running the business.
- Abbott Laboratories made $6.5B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 16.5% a year.
- Free cash flow was $7.4B in fiscal 2025, 16.7% of revenue.
- Abbott Laboratories returned $5.0B to shareholders in fiscal 2025, 68% of free cash flow. The diluted share count rose 0.0%.
- Abbott Laboratories owes $4.0B more than it holds in cash, about 0.4 years of operating profit.
Market cap
$183.2B
P/E
29.3x
Revenue
$44.3B
Net income
$6.5B
Free cash flow
$7.4B
Operating margin
18.2%
Abbott Laboratories in 30 seconds · fiscal 2025
Are sales growing?
+5.7%
Yes. Sales grew 5.7% last year.
Does it make a profit?
14.7%
Yes. It keeps 14.7% of every sale as profit.
Does profit turn into cash?
16.7%
Yes. 16.7% of sales ends up as free cash.
Is debt under control?
0.4x
Yes. It could repay its debt with 0.4 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
29.3x
One share costs 29.3 times its yearly profit per share. Typical for its sector: 27.9x.
What Abbott Laboratories does
Abbott Laboratories discovers, develops, makes and sells a wide range of healthcare products. It has four reportable segments. Medical Devices covers heart devices such as pacemakers, defibrillators and heart-failure and vascular devices, plus continuous glucose monitors for people with diabetes and devices that treat chronic pain and movement disorders. Diagnostic Products sells lab instruments and tests, rapid tests, and point-of-care systems to hospitals, labs, blood banks and clinics. Nutritional Products sells infant formula (Similac), adult nutrition drinks (Ensure, Glucerna, Pedialyte) and tube-feeding products. The fourth segment, Established Pharmaceutical Products, sells branded generic medicines, made worldwide and sold outside the United States in emerging markets. They treat stomach and liver conditions, women's health, heart and metabolic disease, pain and respiratory illness.
Biggest risks, in its own words
- Borrowing a large amount to pay for the Exact Sciences deal, which would reduce its flexibility.
- Safety concerns about its products, or problems making them, which are complex to manufacture.
- Disruptions in its large, complex global supply chain.
- Changes in health care rules, government programs and cost-cutting efforts that lower prices or demand.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 20, 2026
- Legal name
- ABBOTT LABORATORIES
- CIK
- 0000001800
Abbott Laboratories · ABT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Revenue growth | 24.5% | 1.3% | −8.1% | 4.6% | 5.7% |
| Gross margin | 57.0% | 56.2% | 55.2% | 55.4% | 56.4% |
| Operating margin | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% |
| Net income | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B |
| Net margin | 16.4% | 15.9% | 14.3% | 32.0% | 14.7% |
| Diluted EPS | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Cash | |||||
| Cash from operations | $10.5B | $9.6B | $7.3B | $8.6B | $9.6B |
| Capital expenditure | $1.9B | $1.8B | $2.2B | $2.2B | $2.2B |
| Free cash flow | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B |
| FCF margin | 20.1% | 17.9% | 12.6% | 15.1% | 16.7% |
| Dividends paid | $3.2B | $3.3B | $3.6B | $3.8B | $4.1B |
| Share buybacks | $2.3B | $3.8B | $1.2B | $1.3B | $893M |
| Share count change | 0.2% | −1.4% | −0.9% | −0.1% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $10.2B | $10.2B | $7.3B | $8.0B | $8.9B |
| Debt incl. finance leases | $18.1B | $16.8B | $14.7B | $14.1B | $12.9B |
| Shareholders' equity | $35.8B | $36.7B | $38.6B | $47.7B | $52.1B |
| Net debt / EBITDA | 0.7x | 0.6x | 0.8x | 0.6x | 0.4x |
| Current ratio | 1.9x | 1.6x | 1.6x | 1.7x | 1.6x |
| Interest coverage | 15.8x | 15.0x | 10.2x | 12.2x | 16.3x |
| Returns and quality | |||||
| Return on capital | 16.4% | 16.0% | 12.4% | 13.6% | 11.2% |
| Return on equity | 20.6% | 19.1% | 15.2% | 31.1% | 13.1% |
| Piotroski F-score | 8 | 5 | 6 | 8 | 6 |
| Altman Z'' | 4.1 | 4.2 | 4.2 | 4.7 | 4.9 |
Insiders bought, 12 months
$4.4M
4 insiders
Insiders sold, 12 months
$47.5M
7 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Abbott Laboratories · ABT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | $183.2B | 5.7% | 18.2% | 16.7% | 11.2% | 29.3x | 6 |
| Medtronic MDT | $121.8B | 8.4% | 17.8% | 14.9% | 7.7% | 23.3x | 7 |
| Stryker SYK | $118.2B | 11.2% | 19.5% | 17.1% | 11.3% | 31.7x | 6 |
| Becton Dickinson BDX | $54.0B | 8.2% | 11.8% | 12.2% | 5.5% | 59.2x | 6 |
| GE HealthCare GEHC | $32.9B | 4.8% | 13.4% | 7.3% | 13.3% | 17.2x | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $104.88 a share, the company is worth $183.2B: 29.3 times its earnings of the last four quarters.
Abbott Laboratories grew sales faster than 1 of its 4 similar companies. Its P/E is higher than 2 of 4.
Source: SEC EDGAR XBRL filings (CIK 0000001800). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.